<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153527</url>
  </required_header>
  <id_info>
    <org_study_id>2016-00487</org_study_id>
    <nct_id>NCT03153527</nct_id>
  </id_info>
  <brief_title>Taper Or Abrupt Steroid Stop: TOASSTtrial</brief_title>
  <acronym>TOASST</acronym>
  <official_title>Glucocorticoid Withdrawal and Glucocorticoid-induced Adrenal Insufficiency: a Randomized Controlled Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kantonsspital Baselland Bruderholz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid
      termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In total, 573 patients will be enrolled. Patients will be randomly assigned in a 1:1 ratio to
      either prednisone in decreasing doses over 4 weeks or placebo.

      Patients, treating physicians, and study personnel will be blinded to treatment allocation to
      either prednisone or matching placebo. At inclusion, we will perform a 250 micrograms
      Synacthen® stimulation test. The results of the test will be blinded to treating physicians
      and investigators, and its value to predict clinical outcome will only be assessed after
      completion of the trial. As a safety measure, all patients will be instructed about stress
      coverage as well as signs and symptoms of hypocortisolism and will be provided with emergency
      medication. Patients will be randomized to the standard (tapering) or the experimental
      (matching placebo) arm. Follow-up will be for six months. In order to improve adherence to
      the study and ensure feasibility, follow-up visits in most study centers will be by telephone
      only. Visits will be performed early after stopping glucocorticoids in both arms (i.e. at
      days 7 and 35) to ensure safety; the other two visits will be on days 90 and 180.

      Amendment approved in 1-2018: former exclusion criterion 'status post organ transplantation'
      was revised and deleted
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Standard treatment arm: Prednisone, a synthetic glucocorticoid with intermediate duration of action (biological half-life 18-35 hrs). The detailed characteristics of the compound, marketed under several brand names, can be found at www.swissmedicinfo.ch: Prednison Streuli (Swissmedic registration number: 29349); Prednison Axapharm (Swissmedic registration number: 58761); Prednison Galepharm (Swissmedic registration number: 50821).
Interventional treatment arm: matching placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding of trial participants, treating physicians, study doctors, study nurses, outcome assessors and data analysts will be ensured by using identical-looking placebo, packaged in identical vials as the prednisone verum. Vials will be labeled with &quot;Prednisone or Placebo&quot; in an identical fashion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to any incidence</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time to first occurrence of hospitalization, death, initiation of unplanned systemic glucocorticoid therapy, or adrenal crisis (defined as glucocorticoid-responsive hypotension or shock with or without accompanying symptoms and signs such as weakness, apathy, nausea, vomiting, abdominal pain, hypothermia, hyponatremia [serum sodium &lt; 135 millimole (mM)], hyperkalemia [serum potassium &gt; 5 mM], hypoglycemia [plasma glucose &lt; 3.5 mM]); whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to specific incidence</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Time to first occurrence of individual components of the primary outcome;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative overall systemic glucocorticoid dose</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Cumulative overall systemic glucocorticoid dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative systemic glucocorticoid dose administered to treat or prevent adrenal failure</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Cumulative systemic glucocorticoid dose administered to treat or prevent adrenal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative systemic glucocorticoid dose administered to treat relapse</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Cumulative systemic glucocorticoid dose administered to treat relapse of disease, specified for each disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General health status</measure>
    <time_frame>assessed at days 1, 7, 28, 35, 90,180</time_frame>
    <description>General health status as self-assessed by the participant on a visual analog scale (VAS) from 0 to 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of symptoms and signs of hypocortisolism</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Score of symptoms and signs of hypocortisolism: weakness, hypothermia, nausea, vomiting, abdominal pain, fatigue, dizziness, Blood pressure, serum Na and serum glucose concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance in 250 mcg Synacthen® test</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Performance in 250 mcg Synacthen® test: test assessed day 1 in all participants, plus days 7 and 35 in those followed in centers Bruderholz, Luzern, Aarau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients hospitalized at study entry: length of hospital stay</measure>
    <time_frame>up to 6 months</time_frame>
    <description>In patients hospitalized at study entry: length of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">573</enrollment>
  <condition>Inflammatory Disorder</condition>
  <condition>Autoimmune</condition>
  <arm_group>
    <arm_group_label>Placebo arm (intervention arm)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum group (control/standard arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>If patient is on &gt; 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.</description>
    <arm_group_label>Verum group (control/standard arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Arm</intervention_name>
    <description>The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.</description>
    <arm_group_label>Placebo arm (intervention arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent as documented by signature (Appendix Informed Consent Form)

          -  Age ≥ 18 years

          -  Daily glucocorticoid dose ≥ 7.5 mg prednisone-equivalent at the time of inclusion

          -  Therapy over ≥ 28 days, ≥ 15 mg average daily dose, with a cumulative glucocorticoid
             dose ≥ 420 mg prednisone-equivalent prior to inclusion

          -  Tapering not or no longer mandatory to treat underlying disease

        Exclusion Criteria:

          -  Primary adrenal failure

          -  Treatment with systemic depot glucocorticoids (e.g. intramuscular, epidural)

          -  Incapability to administer glucocorticoid cover treatment in situations of stress

          -  Inability or unwillingness to provide informed consent

          -  Women who are pregnant or breast feeding,

          -  Intention to become pregnant during the course of the study,

          -  Lack of safe contraception, defined as: Female participants of childbearing potential,
             not using and not willing to continue using a medically reliable method of
             contraception for the entire study duration, such as oral, injectable, or implantable
             contraceptives, or intrauterine contraceptive devices, or who are not using any other
             method considered sufficiently reliable by the investigator in individual cases.

          -  Known or suspected non-compliance

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant,

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study,

          -  Previous enrolment into the current study,

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Rutishauser, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Baselland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonas Rutishauser, Prof MD</last_name>
    <phone>+41-61-436 28 03</phone>
    <email>j.rutishauser@unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Departement of Internal Medicine, Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip Schuetz, Prof Dr med</last_name>
      <phone>+41 62 838 95 24</phone>
      <email>schuetzph@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology/Diabetology/Metabolism; University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Donath, Prof Dr Med</last_name>
      <phone>+41 61 265 50 78</phone>
      <email>marc.donath@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology, Immunology, and Allergology, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Villiger, Prof Dr med</last_name>
      <phone>+41-31- 632 31 55</phone>
      <email>peter.villiger@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baselland/Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Rutishauser, Prof Dr med</last_name>
      <phone>+41-61-436 36 71</phone>
      <email>j.rutishauser@unibas.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Primary Health Care, Basel University, Kantonsspital Baselland</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Zeller, Prof Dr med</last_name>
    </contact>
    <contact_backup>
      <phone>+41-61-925 20 75</phone>
      <email>andreas.zeller@unibas.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Internal Medicine, Kantonsspital Baselland/Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Leuppi, Prof Dr med</last_name>
      <phone>+41-61-925 21 80</phone>
      <email>joerg.leuppi@ksbl.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Departement of Internal medicine, Luzerner Kantonsspital</name>
      <address>
        <city>Luzern 16</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Henzen, Prof Dr med</last_name>
      <phone>+41-41-205 51 03</phone>
      <email>christoph.henzen@luks.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Brändle, Prof Dr med</last_name>
      <phone>+41-71-494 61 21</phone>
      <email>michael.braendle@kssg.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

